Pfizer Says EC Approves Vizimpro for Non-Small Cell Lung Cancer

Date : 03/04/2019 @ 16h33
Source : Dow Jones News
Valeur : Pfizer Inc (PFE)
Cours : 37.5  0.24 (0.64%) @ 01h58
Pfizer Cours Graphique
After Hours
Last Trade
Last $ 37,60 ▲ 0,10 (0,27%)

Pfizer Says EC Approves Vizimpro for Non-Small Cell Lung Cancer

Pfizer (NYSE:PFE)
Graphique Historique de l'Action


De Mai 2018 à Mai 2020

Plus de graphiques de la Bourse Pfizer

By Michael Dabaie

 

Pfizer Inc. (PFE) said Wednesday the European Commission approved Vizimpro as monotherapy for the first-line treatment of lung cancer.

The EC approved Vizimpro for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor-activating mutations. The EC's approval was supported by data from the Archer 1050 Phase 3 study. The primary endpoint was progression-free survival as determined by blinded Independent Radiologic Central review. A statistically significant improvement in PFS as determined by the IRC was demonstrated, the company said.

In 2012, Pfizer and SFJ Pharmaceuticals agreed to conduct the Archer 1050 study across multiple sites. SFJ Pharmaceuticals provided the funding and conducted the trial to generate the clinical data used to support this application. Pfizer retains all rights to commercialize Vizimpro globally.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

April 03, 2019 10:18 ET (14:18 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Dernières Valeurs Consultées
EU
GLE
Société Gé..
EU
ALU
ALCATEL-LU..
EU
PX1
CAC 40
ORA
Orange
FX
EURUSD
Euro vs Do..
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.


Inscrivez-vous maintenant pour créer votre liste d'actions personnalisée, en streaming.

Les cours EURONEXT (CAC 40, etc. ) et FOREX (les devises) sont en direct si connecté.
NYSE, AMEX, et ASX sont en différé d'environ 20 minutes. Les autres cours sont en différé d'environ 15 minutes.

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

P: V:fr D:20200524 23:32:03